381 reports of this reaction
1.5% of all CANAKINUMAB reports
#16 most reported adverse reaction
DIVERTICULITIS is the #16 most commonly reported adverse reaction for CANAKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 381 FDA adverse event reports linking CANAKINUMAB to DIVERTICULITIS. This represents approximately 1.5% of all 25,877 adverse event reports for this drug.
Patients taking CANAKINUMAB who experience diverticulitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIVERTICULITIS is a less commonly reported adverse event for CANAKINUMAB, but still significant enough to appear in the safety profile.
In addition to diverticulitis, the following adverse reactions have been reported for CANAKINUMAB:
The following drugs have also been linked to diverticulitis in FDA adverse event reports:
DIVERTICULITIS has been reported as an adverse event in 381 FDA reports for CANAKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIVERTICULITIS accounts for approximately 1.5% of all adverse event reports for CANAKINUMAB, making it a notable side effect.
If you experience diverticulitis while taking CANAKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.